TPPB
Modify Date: 2024-01-02 18:11:38
TPPB structure
|
Common Name | TPPB | ||
|---|---|---|---|---|
| CAS Number | 497259-23-1 | Molecular Weight | 501.541 | |
| Density | 1.2±0.1 g/cm3 | Boiling Point | 728.8±60.0 °C at 760 mmHg | |
| Molecular Formula | C27H30F3N3O3 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | 394.6±32.9 °C | |
Use of TPPBTPPB is a cell-permeable benzolactam-derived protein kinase C (PKC) activator with a Ki of 11.9 nM. |
| Name | (2E,4E)-N-[(2S,5S)-5-(hydroxymethyl)-1-methyl-3-oxo-2-propan-2-yl-2,4,5,6-tetrahydro-1,4-benzodiazocin-8-yl]-5-[4-(trifluoromethyl)phenyl]penta-2,4-dienamide |
|---|---|
| Synonym | More Synonyms |
| Description | TPPB is a cell-permeable benzolactam-derived protein kinase C (PKC) activator with a Ki of 11.9 nM. |
|---|---|
| Related Catalog | |
| Target |
PKC:11.9 nM (Ki) |
| In Vitro | By use of a cell line derived from an Alzheimer’s disease patient, significant enhancement of sAPPα secretion is achieved at 1 μM concentration for TPPB (Compound 5e)[1]. TPPB has a role against Aβ25-35-induced neurotoxicity in PC12 cells. TPPB at concentration of 1 μM could antagonize Aβ25-35 induced cell damage. TPPB could increase the phosphorylation of Akt, PKC, MARCKS and MAPK, which are inhibited by Aβ25-35 treatment. TPPB inhibits the activation of caspase-3 induced by Aβ25-35[2]. |
| In Vivo | TPPB is evaluated for induction of hyperplasia after topical application to the shaved backs of outbred Sencar mice and shows a modest response at 300 μg[1]. |
| Cell Assay | 24 h after plating 2×104 pheochromocytoma PC12 cells in each well of a 96 well plate, cells are incubated with TPPB at a series of concentration (0.1, 0.5, 1, 5, 10, 20 μM). Twelve to 24 h later, the original media is replaced with media containing MTT at a final concentration of 0.5 g/L for 4 h. Cell viability is evaluated with MTT assays[2]. |
| Animal Admin | Mice: Mice are 7 weeks old at the beginning of the treatments and are in the resting phase of the hair cycle. TPPB is applied once or else are applied twice weekly for a total of four applications. Two animals are treated at each dose of compound, and 72 h after the last application, the animals are euthanized. Two portions of treated skin are removed from each animal, fixed in neutral buffered formalin, and stained with hematoxylin and eosin for histological analysis[1]. |
| References |
| Density | 1.2±0.1 g/cm3 |
|---|---|
| Boiling Point | 728.8±60.0 °C at 760 mmHg |
| Molecular Formula | C27H30F3N3O3 |
| Molecular Weight | 501.541 |
| Flash Point | 394.6±32.9 °C |
| Exact Mass | 501.223938 |
| PSA | 85.16000 |
| LogP | 3.09 |
| Vapour Pressure | 0.0±2.5 mmHg at 25°C |
| Index of Refraction | 1.572 |
| Storage condition | 2-8℃ |
| (2E,4E)-N-[(2S,5S)-5-(hydroxymethyl)-1-methyl-3-oxo-2-(propan-2-yl)-1,2,3,4,5,6-hexahydro-1,4-benzodiazocin-8-yl]-5-[4-(trifluoromethyl)phenyl]penta-2,4-dienamide |
| (2E,4E)-N-[(2S,5S)-5-(Hydroxymethyl)-2-isopropyl-1-methyl-3-oxo-1,2,3,4,5,6-hexahydro-1,4-benzodiazocin-8-yl]-5-[4-(trifluoromethyl)phenyl]-2,4-pentadienamide |
| 2,4-Pentadienamide, N-[(2S,5S)-1,2,3,4,5,6-hexahydro-5-(hydroxymethyl)-1-methyl-2-(1-methylethyl)-3-oxo-1,4-benzodiazocin-8-yl]-5-[4-(trifluoromethyl)phenyl]-, (2E,4E)- |
| tppb |
| (2S,5S)-(E,E)-8-(5-(4-(trifluoromethyl)phenyl)-2,4-pentadienoylamino)benzolactam |